H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $25 and keeps a Buy rating on the shares. The company’s nine-month enrollment completion in the pivotal Phase 3 HAELO trial of lonvo-z shows the pull for a one-time therapy, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Nvidia to invest $5B in Intel, ABC pulls ‘Jimmy Kimmel Live!’: Morning Buzz
- Intellia Therapeutics completes enrollment in Phase 3 HAELO study of Ionov-z
- Cathie Wood Bets on AMD, Bullish, and Figma; Trims Tempus AI, Roku
- Cathie Wood’s ARK Investment buys 615.8K shares of Intellia Therapeutics today
- Cathie Wood Buys the Dip in Figma Stock, Sells Roku and Genius Sports